References
- O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 accf/aha guideline for the management of st-elevation myocardial infarction: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013;61:e78-140
- Eapen ZJ, Tang WH, Felker GM, et al. Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. Circ Cardiovasc Qual Outcomes 2012;5:594-600
- Menees DS, Peterson ED, Wang Y, et al. Door-to-balloon time and mortality among patients undergoing primary pci. N Engl J Med 2013;369:901-9
- Callender T, Woodward M, Roth G, et al. Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med 2014;11:e1001699
- Chronic heart failure: National clinical guideline for diagnosis and management in primary and secondary care: Partial update. London: 2010
- Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013;62:e147-239
- Hlatky MA, Mark DB. The high cost of implantable defibrillators. Eur Heart J 2007;28:388-91
- LaPointe NM, Al-Khatib SM, Piccini JP, et al. Extent of and reasons for nonuse of implantable cardioverter defibrillator devices in clinical practice among eligible patients with left ventricular systolic dysfunction. Circ Cardiovasc Qual Outcomes 2011;4:146-51
- NICE G. National Clinical Guideline Centre. The Management of Chronic Heart Failure in Adults in Primary and Secondary Care. 2010. Available from: http://guidance.nice.org.uk/CG108/Guidance/pdf/English
- Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 2011;13(Suppl 2):ii13-17
- Larose E, Rodes-Cabau J, Pibarot P, et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol 2010;55:2459-69
- Gerczuk PZ, Kloner RA. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol 2012;59:969-78
- Koch-Weser J. Drug therapy: Metoprolol. N Engl J Med 1979;301:698-703
- Ibanez B, Macaya C, Sanchez-Brunete V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation 2013;128:1495-503
- Pizarro G, Fernandez-Friera L, Fuster V, et al. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (effect of metoprolol in cardioprotection during an acute myocardial infarction). J Am Coll Cardiol 2014;63:2356-62
- Ibanez B, Fuster V, Macaya C, et al. Study design for the “effect of metoprolol in cardioprotection during an acute myocardial infarction” (metocard-cnic): a randomized, controlled parallel-group, observer-blinded clinical trial of early pre-reperfusion metoprolol administration in ST-segment elevation myocardial infarction. Am Heart J 2012;164:473-80. e475
- Antoniucci D. Block the ischemia and reperfusion damage: an old adjunctive drug for a new reperfusion strategy. J Am Coll Cardiol 2014;63:2363-4
- Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005;366:1622-32
- Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007;370:1929-38
- Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace 2009;11:716-26
- Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008;52:1111-21